-logo-1200x675.PNG?v=20210211152252)
Profound Medical Corp. (TSE:PRN - Get Free Report) insider Thomas Michael Tamberrino purchased 3,755 shares of the company's stock in a transaction on Monday, August 17th. The shares were bought at an average price of C$9.44 per share, for a total transaction of C$35,447.20. Following the completion of the transaction, the insider directly owned 53,573 shares in the company, valued at C$505,729.12. This represents a 7.54% increase in their position.
Profound Medical Stock Performance
Shares of TSE:PRN opened at C$9.20 on Tuesday. The company has a 50 day moving average of C$9.87 and a 200-day moving average of C$9.35. The company has a current ratio of 6.46, a quick ratio of 14.98 and a debt-to-equity ratio of 14.82. The firm has a market cap of C$334.31 million, a P/E ratio of -9.29 and a beta of 1.30. Profound Medical Corp. has a twelve month low of C$5.23 and a twelve month high of C$12.40.
Profound Medical (TSE:PRN - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported C($0.37) EPS for the quarter. The firm had revenue of C$3.53 million for the quarter. Profound Medical had a negative return on equity of 62.45% and a negative net margin of 170.92%. As a group, analysts anticipate that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, Raymond James Financial upgraded Profound Medical from a "moderate buy" rating to a "strong-buy" rating in a report on Monday, July 27th. Eight research analysts have rated the stock with a Buy rating, sixteen have given a Moderate Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Profound Medical presently has a consensus rating of "Moderate Buy" and a consensus price target of C$9.20.
Check Out Our Latest Stock Report on Profound Medical
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
